"Criado em 1985, o Centro de Hematologia e Hemoterapia da Unicamp – Hemocentro da UNICAMP, atua como Centro de Referência em nível terciário e quaternário para a região de Campinas nas áreas de Hematologia e Hemoterapia, atendendo a uma população de aproximadamente 6 milhões de habitantes distribuídos em cerca de 120 municípios. As atividades assistenciais do Hemocentro são realizadas por suas duas Divisões Administrativas: Hematologia e Hemoterapia Sistema da Qualidade A certificação do Hemocentro da Unicamp pelas normas ISO/NBR 9002:1994 ocorreu em janeiro de 2002. Nos anos seguintes, a certificação foi atualizada com base nas novas versões da norma ISO/NBR 9001 (2000, 2005 e 2008)."

During the past decade, Hemocentro-Unicamp conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 2 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Hemocentro-Unicamp" are "B-Cell Lymphomas" (1 trials), "Gaucher Disease" (1 trials), "Multiple Myeloma" (1 trials) and "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)" (1 trials). Many other conditions were trialed in "Hemocentro-Unicamp" in a lesser frequency.

Most popular intervention types in "Hemocentro-Unicamp" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (2 trials), "Bortezomib" (1 trials), "Carfilzomib" (1 trials), "Cytarabine" (1 trials) and "Eliglustat tartrate" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hemocentro-Unicamp" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Hemocentro-Unicamp". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Hemocentro-Unicamp, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hemocentro-Unicamp, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".